00:00It affects more than 100,000 people in Italy, with prevalence between 30 and 50 years and without gender differences,
00:06limiting mobility due to joint pain and swelling and impacting quality of life.
00:11It is active psoriasis arthritis, a chronic and serious systemic inflammatory condition
00:16that affects both joints and skin.
00:19Thanks to the free route of AIFA, the extension of reimbursability of the monoclonal antibiotic bimechizumab for this pathology,
00:25after having granted it in 2023 for psoriasis plaque from moderate to severe,
00:29patients suffering from active psoriasis arthritis will be able to take advantage of a new therapeutic option
00:34able to offer a high level of disease control in skeletal and cutaneous muscle failures.
00:40Bimechizumab is a monoclonal antibody that links two fundamental inflammatory factors for the development of the disease,
00:48which are interleukin A17 and F.
00:51It was finally approved also for psoriasis arthritis
00:55and therefore we can block both the progression from psoriasis to arthritis,
01:03but also the pain and the arthritis itself, using a single drug that blocks two inflammatory factors.
01:12To confirm the effectiveness, tolerability and safety of the monoclonal antibody in the treatment of active psoriasis arthritis,
01:19the results at 52 weeks of the B-Complete B-Vital open extension study,
01:23based on the data at 16 weeks of the B-Complete study and on those at 52 weeks of the B-Optimal study.
01:30The long-term data show that more than 6 patients out of 10 treated continuously with bimechizumab
01:36have obtained a complete cutaneous clearance and almost 1 in 2 had a minimal disease activity at the 52nd week.
01:44From an rheumatological point of view, the most interesting result is linked to the number of patients
01:50who achieve a result called MDA, that is Minimal Disease Activity.
01:54This MDA, which is a situation very close to complete remission,
01:59is achieved in a very high percentage of patients,
02:02so this gives us great hope in real life to achieve the same result in the patients we see in the clinic.
02:08The introduction of this biological therapy in the range of treatment options available to clinicians
02:13gives patients the hope of a better quality of life.
02:17UCB Pharma has been doing research in various fields for almost 100 years,
02:22but lately it has concentrated its research in immunology and neurology.
02:27Last year it invested almost 30% of its turnover, which is 5.3 billion, in research and development,
02:35and we do it with a precision research based on antibodies and small molecules.
02:40It is a commitment that has certainly already yielded great results,
02:44this is a very important indication that we are launching today,
02:48but it will go on and, in short, new answers should really come
02:53for the needs of patients who are still not satisfied.
Comments